Streetwise Articles

Gout, Kidney Stones, Liver Disease & Cannabinoids
Source: Danny Deadlock for Streetwise Reports  (9/15/17)
Danny Deadlock, founder of, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. More >

Biopharma Gets Green Light for Hypertension Study
Source: Streetwise Reports  (9/13/17)
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. More >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy
Source: Streetwise Reports  (9/1/17)
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components.
More >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena
Source: Streetwise Reports  (8/30/17)
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
More >

Analyst Says Cell Therapy Company's Move Decreases Risk
Source: Streetwise Reports  (8/23/17)
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. More >

Medical Cannabis Innovator Set to Go Public
Source: Streetwise Reports  (8/18/17)
A licensed producer of medical cannabis in Canada will begin trading on the Canadian Securities Exchange on Aug. 21. More >

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection
Source: Streetwise Reports  (8/16/17)
Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.
More >

'Keep a Close Eye On' This Regenerative Medicine Firm
Source: Streetwise Reports  (8/16/17)
In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."
More >

Maxim Raises Target Price of Biotech Company
Source: Streetwise Reports  (8/16/17)
A year-over-year increase in sales of its flagship product, and the prospect that its technology could be used to promote the efficacy of cell therapies, helped spur a target price increase on this biotech.
More >

Cell Therapy for Melanoma Impresses in
Phase 2

Source: Streetwise Reports  (8/9/17)
Positive clinical data for this U.S. company's immunotherapy for metastatic melanoma are both encouraging and impressive, says one analyst.
More >

Over-the-Counter Treatments for Joint Pain and Women's Health Propel Company into New Markets
Source: Streetwise Reports  (8/9/17)
With the launch of its over-the-counter combination treatment for joint pain and new licensing agreements for feminine lubrication product Zestra, this San Diego-based company is expanding both its therapeutic and international reach.
More >

Company Developing Cannabinoid-Based Drug Therapy for Concussions Completes Reverse Takeover
Source: Streetwise Reports  (8/7/17)
A drug developer working on a treatment for concussions expects to begin trading on the TSX Venture Exchange on Aug. 8. More >

Kenneth Ameduri

This Just Changed Everything: Green Profits Are Being Unleashed
Source: Kenneth Ameduri for Streetwise Reports  (8/3/17)
Kenneth Ameduri, founder of Crush the Street, discusses why he believes now is a good time to take advantage of cannabis investing opportunities. More >

Loan Provides Driver for Growth for Medical Device Firm
Source: Streetwise Reports  (8/2/17)
Brian Marckx, analyst with Zacks Small-Cap Research, reports that a $20 million loan received by a U.S.-based medical device company could further fuel growth. More >

Canadian Medical Cannabis Provider Expanding into US Market Through RTO
Source: Streetwise Reports  (7/25/17)
A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26. More >

DNA-Based Compound Shuts Down Seasonal Flu in Preclinical Study
Source: Streetwise Reports  (7/19/17)
A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018. More >

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating
Source: Streetwise Reports  (7/19/17)
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company. More >

Biotech with Alzheimer's Focus Makes Progress on Several Fronts
Source: Streetwise Reports  (7/18/17)
In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development. More >

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17
Source: Streetwise Reports  (7/13/17)
If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them. More >

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange
Source: Streetwise Reports  (7/11/17)
A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14. More >

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial
Source: Streetwise Reports  (7/5/17)
With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.
More >

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story'
Source: Streetwise Reports  (6/29/17)
Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs. More >

With Completion of Offer, Analyst Says This Biotech Stock Could Triple
Source: The Life Sciences Report  (6/28/17)
A Canadian company with its lead drug candidate in a Phase 3 trial recently closed an offering that raised CA$10 million for future research, which has one analyst contemplating the potential for "3x upside." More >

Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray
Source: The Life Sciences Report  (6/21/17)
A San Diego-based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. More >

Phase 3 Trial for Inovio's VGX-3100 in Cervical Dysplasia Gets FDA Go-Ahead
Source: The Life Sciences Report  (6/14/17)
Now that the FDA has lifted its clinical hold on Phase 3 study of Inovio Pharmaceutical's immunotherapy for cervical dysplasia, three analysts are making note of what the progress means for both the company and investors. More >

Showing Results: 26 to 50 of 812 Prev Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe